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Background: Eslicarbazepine acetate (ESL, Aptiom®) is a once-daily (QD) anticonvulsant, approved as adjunctive
treatment of partial-onset seizures (POS). It is extensively converted after oral administration to eslicarbazepine, and
is believed to exert its effect through inhibition of voltage-gated sodium channels. The possible role of ESL as
monotherapy to treat POS has not yet been established.
Methods: This study was an 18-week, multicenter, randomized double-blind trial of gradual conversion to ESL
monotherapy in adults with POS not well controlled by 1–2 antiepileptic drugs (AEDs), using historical data as the
control. The study comprised an 8-week baseline period, a 2-week titration period, a 6-week AED conversion period,
a 10-week monotherapy period, and either a 1-week taper period or optional entry to an open-label extension
study. The primary endpoint compared the Kaplan–Meier (KM)-estimated 112-day exit rate with a threshold value
calculated from the historical controls.
Results: There were 172 randomized patients; 154 (90%) entered the AED conversion period and 121 (70%)
completed the study. The KM-estimated exit rates [confidence interval (CI)] were 15.6% [8.1–28.7%] for ESL
1200 mg, and 12.8% [7.5–21.5%] for ESL 1600 mg. The upper limits of the 95% CI KM-estimates were below the
pre-specified threshold for historical control of 65.3%, indicating that ESL was efficacious in reducing seizure-related
exits, compared with historical control. During the 18-week double-blind treatment period, median reductions in
standardized seizure frequency occurred with ESL 1200 mg (36.1%) and ESL 1600 mg (47.5%). The responder rates
(a 50% or greater reduction in seizure frequency from baseline) during the 18-week double-blind period and the
monotherapy period, respectively, were 35.2% and 38.9% for ESL 1200 mg, and 46.0% and 46.0% for ESL 1600 mg.
The overall adverse event profile was consistent with the known safety profile of ESL.
Conclusions: These findings indicate that ESL monotherapy (1200 and 1600 mg QD) was efficacious and well
tolerated in this study.
Trial registration: NCT01091662; EudraCT No. 2010-018684-42.
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The incidence of epilepsy worldwide has been estimated
to be between 16 and 51 per 100,000 (age-adjusted) [1].
Antiepileptic drugs (AEDs) are the mainstay of epilepsy
treatment [2]. AED monotherapy is generally preferred
to adjunctive therapy, due to the greater risk of adverse
events (AEs) and adverse drug interactions with combin-
ation therapy [3]. Moreover, AED monotherapy is valu-
able for certain types of patients, including women, the
elderly, and those with co-morbid conditions, for whom
AED toxicity and drug interactions may have additional
consequences [4,5]. There is an unmet clinical need for
new AEDs that are both effective and well tolerated [4],
for use as monotherapy in the treatment of patients with
epilepsy.
Eslicarbazepine acetate (ESL) is an AED; a member of
the dibenzazepine family. ESL is structurally different
from the other dibenzazepines, carbamazepine (CBZ) and
oxcarbazepine (OXC) [6]. Following oral administration,
ESL undergoes first-pass hydrolysis in the liver, being rap-
idly metabolized to the active metabolite, eslicarbazepine
[7,8]. Eslicarbazepine inhibits sodium currents by binding
to voltage-gated sodium channels (VGSCs) and stabilizing
the inactivated state of the channel and, compared with
CBZ, shows a higher relative affinity for the inactive
versus the resting state of VGSCs [9]. Eslicarbazepine has
an apparent half-life of 13–20 hours in plasma [10] and
20–24 hours in cerebrospinal fluid [11], which supports
once-daily (QD) dosing.
The efficacy and safety of ESL as adjunctive therapy
in adults with partial-onset seizures (POS) is well
established [12-15]. ESL (Aptiom®) was approved by
the European Medicines Agency in 2009 (as Zebinix®)
for adjunctive therapy in adults with POS with or
without secondary generalization [16], and by the US
Food and Drug Administration in November 2013 as
an adjunctive treatment for POS [10]. The potential
role of ESL as monotherapy for POS has not previ-
ously been investigated.
Here we report the results of a phase III clinical trial
that evaluated the efficacy and safety of ESL as mono-
therapy for patients with POS not well controlled by
their current AEDs. Efficacy was evaluated by compari-
son with a historical control group (an approach advo-
cated by French et al., 2010 [17]). Some previous studies
(e.g., for zonisamide and pregabalin) used an active-
control non-inferiority design to investigate the efficacy
of AEDs as monotherapy [18,19]. Such trials allow direct
comparison with active treatment, but are susceptible to
false positive findings of equivalence [20] if the placebo
response rate is high, or if subjects with unusually low
risks of recurrence are recruited. Trials designed to show
statistical superiority over a historical control can pro-
vide complementary evidence of efficacy. This trial usesan identical protocol to study 045, which was performed
in a North American population [21].
Methods
The study (ClinicalTrials.gov identifier: NCT01091662;
EudraCT No. 2010-018684-42) was performed between
June 2010 and November 2012, and was designed and
conducted in accordance with all relevant regulations
and guidelines. The protocol was approved by the
Institutional Review Board (Copernicus Group IRB) and
an independent ethics committee. Written informed
consent was obtained from all patients.
Patients
Table 1 shows the key inclusion and exclusion cri-
teria. Eligible patients were 16 to 70 years of age,
with partial epilepsy, as defined by the International
League Against Epilepsy [22], a history of seizures, an
electroencephalogram consistent with partial epilepsy,
and absence of a progressive structural abnormality,
as shown by a computerized tomography or magnetic
resonance imaging scan within the previous 10 years.
During the 8 weeks prior to screening, patients must
have had at least four POS, and no seizure-free
period ≥4 weeks in duration. They must also have
been receiving stable doses of 1–2 AEDs for 4 weeks
prior to screening. Those receiving two AEDs at
screening were enrolled if at least one AED was not a
sodium channel blocker (phenytoin, CBZ, OXC, lamo-
trigine) and at least one was not in the upper dose
range (more than two-thirds of the defined daily dose;
Table 2).
Procedures
The study used a “withdrawal to monotherapy” design.
The effects of active treatment were compared with
those of a virtual placebo historical control group,
defined by French et al. [17]. Use of a historical con-
trol (based on the exit rates in eight different mono-
therapy studies of similar design and duration to the
current study, including randomization as done in the
original studies) eliminated the need for a placebo
group, meaning that all patients received active treat-
ment. Patients were screened at 50 investigational sites
(25 US; 25 ex-US). Those who successfully completed
screening procedures at 41 investigational sites (18 US
and 23 ex-US) entered an 8-week baseline period for
assessment of seizure frequency. Patients meeting all
inclusion criteria were randomized 2:1 to receive ESL
1600 or 1200 mg QD for 18 weeks. 1200 mg QD was
selected as the highest dose to have been shown to be
effective and well tolerated in adjunctive trials. Based
on evidence with other AEDs used as monotherapy, it
was postulated that the higher dose of 1600 mg QD
Table 1 Patients; inclusion and exclusion criteria
Major inclusion criteria Major exclusion criteria
• Male and female patients aged ≥16 to ≤70 years with partial epilepsy
(defined by the International League Against Epilepsy, 1981 [19]) and a
medical history of seizures.
• Patients with only simple partial seizures without a motor component.
• Presence of generalized seizure syndromes.
• Absence of confounding factors (e.g. pseudoseizures, syncope). • History of pseudoseizures.
• Documented electroencephalography recording consistent with
partial-onset epilepsy and documented computerized tomography or
magnetic resonance imaging scan showing absence of a progressive
structural abnormality (within 10 years prior to screening).
• Current seizures relating to acute medical illness, or seizures secondary
to metabolic, toxic or infectious disorder or drug abuse.
• ≥4 partial onset seizures 8 weeks prior to screening with no 4-week
seizure-free period.
• Status epilepticus within 2 years prior to screening.
• Treatment with a stable dose of 1–2 AEDs in the 4 weeks prior to
screening. In the situation where a patient was receiving two AEDs at
screening, the patient was enrolled if:
• Seizures only occurring in a cluster pattern.
- One of the two AEDs was not one of the following sodium channel
blockers: phenytoin, carbamazepine, oxcarbazepine, or lamotrigine;
and
• Psychiatric history, including major depressive episode within 6 months,
active suicidal plan or intent within the past one month, history of
suicide attempt, significant psychiatric disorder, or alcohol or substance
abuse within 2 years.
- The second of the 2 AEDs was not being dosed in the upper dose
range (defined as greater than approximately two-thirds of the
defined daily dose*).
• In elderly patients (65–70 years), no additional/potential health
complications.
*Defined daily doses of AEDs are shown in Table 2.
AED = antiepileptic drug.
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in the monotherapy setting. Randomization was per-
formed using an interactive voice-response system to
associate each patient with double-blind clinical trial
material (‘kits’) and a randomization number. TheTable 2 Defined daily dose (DDD) for concomitant AEDs






Lamotrigine* 200 mg (200 mg with enzyme inducers; 100 mg with valp
Lacosamide† 300 mg





Tiagabine 20 mg (30 mg with enzyme inducers)
Topiramate 200 mg (300 mg with enzyme inducers)
Vigabatrin 1400 mg
Valproate 1000 mg
Zonisamide 140 mg (200 mg with enzyme inducers)
Note: The DDD is the assumed average maintenance dose per day for a drug used
*Sodium channel blockers; †Adult DDD information from product label.
DDD = defined daily dose; AED = antiepileptic drug.randomization list was prepared by a third party using a
random number generator, following a permutated-block
design (block size = 6). Placebo capsules to match over-
encapsulated ESL 400 mg and 600 mg were supplied to






roate) 300 mg (400 mg with enzyme inducers; 150 mg with valproate)
200–400 mg





30 mg (60 mg with enzyme inducers)
300 mg (600 mg with enzyme inducers)
2000 mg
1500 mg
200 mg (400 mg with enzyme inducers)
for its main indication in adults [32].
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400 mg QD during Week 1 and 800 mg QD during
Week 2; those patients randomized to 1600 mg ESL QD
received 600 mg QD during Week 1 and 1200 mg QD
during Week 2 (Figure 1). The doses of AEDs being used
at baseline were then gradually reduced (by 50% over
the next 3 weeks, and to zero over the subsequent
3 weeks). When two AEDs were being taken, both drugs
were withdrawn concurrently (Figure 1). Throughout
the 6-week conversion period, and for the next 10 weeks,
patients continued to receive their allocated ESL dose
(1200 or 1600 mg QD). After the first 3 days of the 1-
week taper period, ESL doses were down-titrated from
1200 to 600 mg QD, and from 1600 to 800 mg QD. Pa-
tients who completed the first 3 weeks of double-blind
treatment, and who subsequently completed, discontin-
ued, or exited for reasons other than safety were eligible
to participate in a long-term safety open-label extension
study (long-term data will be presented separately).
Assessments
The patients were evaluated in clinic at baseline, at
randomization, and after the start of ESL dosing, at
Weeks 1, 2, 5, 8, 11, 14, 18, and 19. Additionally there
was telephone contact at Weeks 3, 4, 6, 7, 9, 10, 12,
13, 15, 16, and 17.
Primary endpoint
Seizure data were collected using a seizure diary, com-
pleted daily by the patients, throughout the study. Inves-
tigators reviewed the seizure diaries with the patients
during clinic visits, to decide whether or when patients
had met one of the five prospectively defined exit criteria
(signifying worsening seizure control) before the end ofFigure 1 Study design. Patients randomized to 1600 mg QD of study dru
period and down-titrated from 1600 to 800 mg QD after 3 days of the star
titrated from 400 to 800 mg to 1200 mg QD over the 2-week titration peri
taper period. Patients started other AEDs during the taper period. AED = an
period.the 16-week study period (shown in Figure 1): one epi-
sode of status epilepticus; one secondary generalized
partial seizure (for patients who did not have generalized
seizures in the 6 months before screening); a doubling of
any consecutive 28-day seizure rate, compared with the
highest such rate during the baseline period; a doubling
of any consecutive 2-day seizure rate, compared with the
highest such rate during the baseline period (or 3
seizures in 2 days, if the highest rate during the baseline
period was 1 seizure per 2 days); worsening of seizures,
or an increase in seizure frequency considered serious or
requiring intervention, as judged by the investigator.
The exit criteria were developed on the basis of histor-
ical and baseline data. For the two criteria related to
doubling of seizure rates, the analysis of the primary
endpoint was conducted using seizure rates calculated
by the study statisticians. The primary efficacy endpoint,
i.e., the exit rate for a treatment arm, is defined as the
proportion of patients meeting at least one of the above
exit criteria during the 16-week (112-day) study period.
Treatment was considered effective (and the null
hypothesis was rejected) if the upper 95% confidence
limit (UCL) for the exit rate (estimated using Kaplan–
Meier methodology) was below the lower limit of the
pre-specified prediction interval (65.3%) calculated from
historical controls [17].
Secondary endpoints
The key secondary endpoint was the seizure-free rate
(%) during the 10-week monotherapy period. Additional
secondary endpoints included: seizure-free rate during
the last 4 weeks on ESL monotherapy; completion rate
(patients completing 18 weeks of double-blind treatment
[%]); completion rate for the 10-week monotherapyg titrated from 600 to 1200 to 1600 mg QD over the 2-week titration
t of the 1-week taper period. Patients randomized to 1200 mg QD
od and down-titrated from 1200 to 600 mg QD after 3 days of start of
tiepileptic drug; QD = once daily; TiP = titration period; TpP = taper
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(between the baseline period and the 18-week double-
blind period or the 10-week monotherapy period);
responder rate (proportion of patients with ≥50% reduc-
tion in seizure frequency, between the baseline period
and the double-blind period or the monotherapy period);
change in standardized seizure frequency by seizure type
(between the baseline and monotherapy periods); re-
sponder rate by seizure type; change from baseline in
Quality Of Life In Epilepsy (QOLIE-31) scores; change
from baseline in Montgomery–Asberg Depression Rating
Scale (MADRS) scores (for all patients, and for patients
with a MADRS score ≥14 at randomization).
Safety and tolerability
AE reports were collected from patients at each clinic
visit, from the time they provided informed consent, to
the end of the study. AEs were coded according to their
respective system organ class and preferred term using
Medical Dictionary for Regulatory Activities (MedDRA)
version 13.1. The occurrence and intensity (mild, moder-
ate, or severe) of AEs were recorded by the investigators.
Serious AEs were reported separately; classification of
AEs as “serious” was at the judgment of the investigator.
Treatment-emergent AEs (TEAEs) were defined as those
AEs that occurred on or after the first dose of the study
drug. Summary statistics for TEAEs were calculated for
each study period (titration, AED conversion and ESL
monotherapy periods) for both treatment groups and
overall.
Statistical analyses
For the primary efficacy endpoint (exits based on seizure
criteria), a sequential testing procedure for type 1 error
control was pre-specified and implemented. The first
comparison was for the ESL 1600 mg group versus
historical control, followed by the ESL 1200 mg group
versus historical control and then a comparison between
the two groups via log-rank testing. French et al. [17]
calculated a 95% prediction interval based on the exit
rates reported in historical trials. The lower bound of
the prediction interval for a single study is an exit rate
of 65.3% at 112 days [17]. Thus, if the 95% UCL for a
treatment group was <65.3%, then the null hypothesis
(that the exit rate for the test group equals the combined
exit rate derived from the historical controls) could be
rejected. The exit rate was estimated using Kaplan–
Meier methods, using the time to exit observed for each
patient.
Patients were censored if they withdrew from the
study for reasons other than meeting the exit criteria,
or if they completed 112 days of treatment without
meeting the exit criteria. The censor rate for early
withdrawal reported in historical control trials was~10%. Consequently, the protocol specified that if the
withdrawal rate for reasons other than meeting exit cri-
teria exceeded 10%, the additional withdrawals would be
reassigned as exits through random sampling. A second-
ary analysis of the primary endpoint was performed, in
which censored patients were not reassigned as exits,
even if the dropout rate was >10%.
An analysis of the exit rate was also performed,
according to use of AEDs at baseline (for AEDs used in
≥20% of patients), using the same method as above. The
potential effects of covariates on exit rate were assessed
using Cox proportional hazards regression models.
The statistical analyses of the secondary efficacy
endpoints and safety endpoints are described in the
Additional file 1: Appendix S1. All statistical procedures
were performed using SAS version 9.2 or higher. All
statistical tests were two-sided, and the type I error rate
was fixed at 0.05.
Determination of sample size
Patients were randomized in a 2:1 ratio to either ESL
1600 or 1200 mg QD. The exit rate is assumed to be
54% for the 1600 mg QD arm, corresponding to a
weekly hazard rate of 4.85%. This exit rate represents a
39% reduction in the exit hazard rate based on the lower
end of the 80% prediction interval established for
replication in two clinical studies (72.2%; weekly hazard
rate of 8%) and a 20% reduction in the exit hazard rate
based on the lower end of the 95% prediction interval
established for a single clinical study (65.3%; weekly
hazard rate of 6.62%). For ~114 patients randomized to
ESL 1600 mg, and assuming a 10% discontinuation rate
without observed exit events, there was ≥95% chance
that the UCL for the observed exit rate would fall below
72.2%, and a 70% chance that the UCL would fall below
65.3%. Assuming an early dropout rate of 20%, ~200
patients were required to enter the baseline period to
achieve a minimum of 171 randomized patients. Fewer
patients were enrolled at 1200 mg, as the lower dose
arm was included for blinding purposes, and to assess
the possibility of a dose–response relationship (although
the study was not adequately powered to detect a statis-
tical difference between doses).
Study populations
The intention-to-treat (ITT) population consisted of all
randomized patients who received at least one dose of
the study drug; the ITT population was used to evaluate
patient disposition, baseline demographics and charac-
teristics, and safety outcomes. Primary and secondary
efficacy analyses were based on the efficacy (EFF) popu-
lation (all ITT patients who entered the AED conversion
period). An additional analysis of the primary efficacy
endpoint was conducted for the per-protocol population
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protocol deviations).Results
Patient demographics and baseline characteristics
Overall, the ITT population included almost equal pro-
portions of males and females (Table 3). Their median
age was 36.5 years; the majority were white (93.0%) and
living outside the US (75.0%). A small minority (4.7%)
were Hispanic or Latino. At study entry, most patients
(64.5%) were receiving one AED. CBZ and valproic acid
were the most commonly used AEDs during the baseline
period (by ≥20% of patients; Additional file 1: Table S1).
Benzodiazepines were used intermittently (emergency
use) by 1.7% of patients taking ESL 1200 mg and 2.6% of
patients taking ESL 1600 mg. During the baseline period,
the mean maximum 2-day seizure rate was 2.4 and the
mean maximum 28-day seizure rate was 10.5. Demo-
graphics and baseline characteristics of the EFF and per-
protocol populations were comparable to that of the
ITT population (data not shown).Table 3 Demographic and clinical characteristics of the ITT po
Characteristic ESL 1200 mg
(n = 58)
Age, years; median (range) 37.0 (16–60)
Gender, male; n (%) 31 (53.4)
Race; n (%)
White 53 (91.4)





BMI, kg/m2; median (range) 25.6 (17–59)
Maximum consecutive 2-day baseline seizure rate
Mean ± SD 2.2 ± 1.84
Maximum consecutive 28-day baseline seizure rate
Mean ± SD 9.2 ± 6.72
Baseline AEDs used by≥20% patients†; n (%)
Carbamazepine 22 (37.9)
Valproic acid‡ 12 (20.7)
Number of AEDs at baseline†; n (%)
1 41 (70.7)
2 17 (29.3)
*At entry to the baseline period.
†An AED was considered to be used at baseline if it was started at any time prior to
‡Includes all forms of valproic acid (ergenyl chrono, valproate semisodium, valproat
Note: Percentages are calculated based on the number of patients with non-missin
ITT = intention-to-treat; ESL = eslicarbazepine acetate; US = United States; BMI = bodyTreatment groups were generally well balanced in terms
of demographics and baseline characteristics (Table 3),
but there was a greater proportion of Black/African-
American patients in the ESL 1200 mg group (8.6%) than
in the ESL 1600 mg group (0.9%).Patient disposition and adherence to study drug
Of the 274 patients screened, 172 were randomized to
study treatment and began the titration period (the ITT
population; Figure 2). Eighteen patients discontinued
during ESL titration (ESL 1200 mg, n = 4; ESL 1600 mg,
n = 14), and consequently, 154 patients began the con-
version to monotherapy (AED conversion) period (the
EFF population). Nineteen patients discontinued during
the conversion period (ESL 1200 mg, n = 7; ESL 1600 mg,
n = 12). One patient who met an exit criterion during the
conversion period was discontinued from the study, but
then attended two further visits, so was also counted as
having entered the monotherapy period, producing a total
of 136 patients entering the monotherapy period. A total
of 121 patients completed the monotherapy period (6pulation*
ESL 1600 mg Total
(n = 114) (n = 172)
35.5 (16–65) 36.5 (16–65)
52 (45.6) 83 (48.3)
107 (93.9) 160 (93.0)
1 (0.9) 6 (3.5)
6 (5.3) 6 (3.5)
28 (24.6) 43 (25.0)
86 (75.4) 129 (75.0)
24.3 (17–51) 24.7 (17–59)
2.5 ± 1.46 2.4 ± 1.60
11.1 ± 7.94 10.5 ± 7.59
27 (23.7) 49 (28.5)
39 (34.2) 51 (29.7)
70 (61.4) 111 (64.5)
44 (38.6) 61 (35.5)
first dose of study drug and continued into the titration period.
e sodium and valproic acid).
g data in the ITT population in each column.
mass index; SD = standard deviation; AED = antiepileptic drug.
Figure 2 Patient flowchart. *One patient met an exit criterion during the AED conversion period and was discontinued from the study, but
returned for the subsequent visits 6 and 7, and so was also counted as having entered the monotherapy period. AE = adverse event; ITT =
intention-to-treat; ESL = eslicarbazepine acetate; AED = antiepileptic drug.
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from the ESL 1600 mg group).
During the double-blind period, 90% of patients had




During the 16 week study period, 19 patients (12.3%)
met one of the five predefined exit criteria (ESL
1600 mg, n = 12; 1200 mg, n = 7). Patients either met
the exit criteria during the AED conversion period (n = 9)or the monotherapy period (n = 10); one patient who met
an exit criterion during the titration period was not
included in the efficacy analysis. One patient who dropped
out was reassigned as an exit in the ESL 1200 mg arm.
The Kaplan–Meier-estimated exit rate was 12.8% [95% CI
7.5–21.5%] for ESL 1600 mg and 15.6% [8.1–28.7%] for
ESL 1200 mg (Figure 3). Thus the UCLs for the Kaplan–
Meier exit rates (1600 mg, 21.5%; ESL 1200 mg, 28.7%)
were both below the 65.3% threshold calculated from the
historical controls (Figure 4), demonstrating that the exit
rates for the two ESL doses were significantly lower (signi-
fying fewer seizure exits) than those observed for the
Figure 3 Kaplan–Meier plot of time to exit (EFF population). EFF = efficacy; ESL = eslicarbazepine acetate; QD = once-daily.
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ESL dose groups (log-rank test between dose groups, p =
0.633), although the study was not powered to detect a
difference between doses.
The primary efficacy endpoint was also evaluated
for the per-protocol population, and the results were
consistent with those for the EFF population; the
Kaplan–Meier-estimated exit rate was 10.9% [95% CI
5.6–20.5%] for ESL 1600 mg and 12.8% [6.0–26.3%]
for ESL 1200 mg. Again, although the study was not
powered to detect a difference between ESL doses, the
exit rates were similar for both dose groups (p = 0.723).Secondary analyses of the primary endpoint
In a secondary analysis of the primary efficacy endpoint
(without reassignment of ‘non-exit withdrawals’ as exits),
the Kaplan–Meier-estimated exit rates were 12.8% [95%
CI 7.5–21.5%] and 13.6% [6.7–26.5%] for ESL 1600 and
1200 mg, respectively. The difference in exit rates be-
tween ESL dose groups was not statistically significant
(p = 0.861).Figure 4 Kaplan–Meier estimates of exit rate at 112 days
(EFF population). EFF = efficacy; CI = confidence interval; ESL =
eslicarbazepine acetate.A total of 44 patients (EFF population) were taking
CBZ during the baseline period (ESL 1200 mg, n = 21;
1600 mg, n = 23), while 46 patients were taking val-
proic acid (ESL 1200 mg, n = 12; 1600 mg, n = 34).
The Kaplan–Meier-estimated exit rates for patients
taking CBZ at baseline (ESL 1200 mg, 29.3% [95% CI
14.3–54.0%]; ESL 1600 mg, 17.4% [6.9–39.9%]) were
numerically higher than for those not taking CBZ
(ESL 1200 mg, 6.5% [1.7–23.4%]; ESL 1600 mg, 12.8%
[6.9–23.1%]; Figure 5). In contrast, the Kaplan–Meier-
estimated exit rates for patients taking valproic acid at
baseline (ESL 1200 mg, 8.3% [1.2–46.1%]; ESL 1600 mg,
11.8% [4.6–28.4%]) were lower than for those not taking
valproic acid (ESL 1200 mg, 20.3% [10.7–36.6%]; ESL
1600 mg, 16.3% [9.1–28.2%]; Figure 5). Irrespective of
CBZ and valproic acid use during the baseline period, the
UCLs for the Kaplan–Meier-estimated exit rates for both
ESL dose groups were below the 65.3% threshold (calcu-
lated from the historical controls).
The effects of covariates were assessed using a Cox
proportional hazards regression model. The adjusted exit
rates changed minimally when adjusted for baseline seiz-
ure frequency, age, number of overall AEDs, and num-
ber of background AEDs used at baseline.Secondary endpoints
Four patients (7.4% [95% CI 2.1–17.9%]) on ESL
1200 mg and 10 (10% [4.9–17.6%]) on ESL 1600 mg
were seizure free during the 10-week monotherapy
period, while seizure-free rates during the last 4 weeks
of monotherapy were 16.7% [95% CI 7.9–29.3%] for ESL
1200 mg and 17% [10.2–25.8%] for ESL 1600 mg.
Completion rates for the 18-week double-blind treat-
ment period were 75.9% [95% CI 62.4–86.5%] for ESL
1200 mg and 80% [70.8–87.3%] for ESL 1600 mg, and
for the 10-week monotherapy period were 85.4% [95%
CI 72.2–93.9%] for ESL 1200 mg and 90.9% [82.9–
96.0%] for ESL 1600 mg.
Figure 5 Kaplan–Meier estimates of exit rate at 112 days with/without carbamazepine and valproic acid (EFF population). EFF = efficacy;
CI = confidence interval; ESL = eslicarbazepine acetate.
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seizure frequency per 28 days. The median reduction in
standardized seizure frequency between the baseline
period and the 18-week double-blind period was 36.1%
for ESL 1200 mg and 47.5% for ESL 1600 mg; >80% of
patients treated with ESL had fewer seizures during the
18-week double-blind period, compared with the base-
line period. The difference between the ESL dose groups
was not significant (p = 0.563). The median reduction in
standardized seizure frequency between the baseline
period and the monotherapy period was 45.7% for ESL
1200 mg and 52.1% for ESL 1600 mg (Table 4).
Responder rates (% patients with ≥50% reduction in
seizure frequency versus baseline) for ESL 1200 and
1600 mg were 35.2% [95% CI 22.7–49.4%] and 46.0%
[36.0–56.3%] for the double-blind period and 38.9%Table 4 Percentage change from baseline in standardized sei
periods, and responder rate by study period (EFF population
Study period ESL
% change in SSF from baseline for the 10-week monotherapy period
Mean ± SD −42.3
Median −45.7
% change in SFF from baseline for the 18-week double-blind period
Mean ± SD −33.0
Median −36.1
Responder rate
Titration period; n (%) [95% CI] 16 (2
AED conversion period; n (%) [95% CI] 16 (2
Monotherapy period; n (%) [95% CI] 21 (3
Double-blind period; n (%) [95% CI] 19 (3
Responder rate was defined as percentage of patients with a ≥50% reduction in se
based on the number of patients with post-baseline seizure data.
EFF = efficacy; ESL = eslicarbazepine acetate; SSF = standardized seizure frequency (s
deviation; CI = confidence interval; AED = antiepileptic drug.[29.5–58.8%] and 46.0% [41.4–63.0%] for the monother-
apy period, respectively (Table 4).
With the exception of nine patients with simple partial
seizures without motor symptoms, patients with all
other seizure types had reductions in standardized seiz-
ure frequency of between 39% and 80% (between the
baseline and monotherapy periods; Table 5). Responder
rates during the monotherapy period were 41–73% for
all seizure types (again, except for the patients with
simple partial seizures without motor symptoms).
Treatment with ESL was associated with an increase
in total QOLIE-31 scores between baseline and the
end of the monotherapy period (by 4.0 ± 11.5 points
with ESL 1200 mg, and by 4.7 ± 13.7 points with ESL
1600 mg), and a reduction in total MADRS scores
(by 1.6 ± 4.5 points with ESL 1600 mg; unchangedzure frequency during the monotherapy and double-blind
)
1200 mg (n = 54) ESL 1600 mg (n = 100)
± 42.48 −39.2 ± 57.93
−52.1
± 43.33 −37.3 ± 46.26
−47.5
9.6%) [18.0–43.6%] 37 (37.0%) [27.6–47.2%]
9.6%) [18.0–43.6%] 39 (39.0%) [29.4–49.3%]
8.9%) [29.5–58.8%] 46 (46.0%) [41.4–63.0%]
5.2%) [22.7–49.4%] 46 (46.0%) [36.0–56.3%]
izure frequency from baseline. Percentages of responders and 95% CIs are
eizure frequency is standardized to a 28-day frequency); SD = standard
Table 5 Percentage change from baseline in standardized seizure frequency, and responder rate by seizure type
during the monotherapy period (EFF population)
n Median change from baseline (%) Responder rate (%)*
ESL 1200 mg ESL 1600 mg ESL 1200 mg ESL 1600 mg ESL 1200 mg ESL 1600 mg
Simple partial without motor 2 7 22.4 −100.0 0 85.7
Simple partial with motor 17 34 −38.5 −52.0 41.2 52.9
Complex partial 30 53 −70.9 −49.8 66.7 49.1
Partial evolving to secondary generalized 16 33 −51.3 −79.7 50.0 72.7
*Patients with ≥50% reduction; calculated as percentage of patients in ESL dose group.
EFF = efficacy; ESL = eslicarbazepine acetate.
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were apparent in patients with MADRS scores ≥14 at
baseline (4.1 ± 7.6 points with ESL 1600 mg; 6.1 ± 6.7
points with ESL 1200 mg).
Safety
Overall, 116 patients (67%) reported ≥1 TEAE during
the study (60% in the ESL 1200 mg group and 71% in
the ESL 1600 mg group). Among patients who had ≥1
TEAE (n = 116), 78% reported a TEAE that was consid-
ered potentially related to the study drug (less frequent
for ESL 1200 mg [66%] than ESL 1600 mg [83%]). The
most commonly reported TEAEs were headache (25% of
patients), dizziness (17%), nasopharyngitis (8%), nausea
(8%), somnolence (7%), fatigue (6%) and back pain (5%)
(Table 6). A greater proportion of patients reported
TEAEs during the titration period (42%) than the AED
conversion period (37%) and the monotherapy period
(38%). The most common TEAEs reported during the
monotherapy period (in ≥2% of patients) were headache
(12%), back pain and nausea (both 4%), influenza, naso-
pharyngitis, complex partial seizures, and dizziness (2%
each).Table 6 TEAEs affecting ≥5% of patients in any ESL dose
group (ITT population, all periods)






Headache 11 (19.0) 32 (28.1) 43 (25.0)
Dizziness 6 (10.3) 24 (21.1) 30 (17.4)
Nasopharyngitis 4 (6.9) 9 (7.9) 13 (7.6)
Nausea 6 (10.3) 7 (6.1) 13 (7.6)
Somnolence 2 (3.4) 10 (8.8) 12 (7.0)
Fatigue 4 (6.9) 6 (5.3) 10 (5.8)
Back pain 3 (5.2) 6 (5.3) 9 (5.2)
Insomnia 4 (6.9) 3 (2.6) 7 (4.1)
Complex partial seizures 1 (1.7) 6 (5.3) 7 (4.1)
Influenza 3 (5.2) 1 (0.9) 4 (2.3)
Anxiety 3 (5.2) 1 (0.9) 4 (2.3)
TEAE = treatment-emergent adverse event; ESL = eslicarbazepine acetate;
ITT = intention-to-treat.Most TEAEs reported during the study were mild or
moderate in severity. Overall, 64 patients (37%) reported
≥1 TEAE of mild intensity, and 48 (28%) reported ≥1
TEAE of moderate intensity. During the AED conver-
sion and monotherapy periods, severe TEAEs were re-
ported by four patients (3.5% of the ESL 1600 mg group,
2.3% of the total). Eight patients on ESL 1600 mg (7.0%)
and one on ESL 1200 mg (1.7%) reported a treatment-
emergent serious AE; none were fatal. The single serious
AE reported for ESL 1200 mg was atrial flutter (which
occurred prior to dosing with ESL), while the ten serious
AEs reported for ESL 1600 mg (by eight patients) were:
ankle fracture; post-concussion syndrome; tibia frac-
ture; hyponatremia; complex partial seizures; partial
seizures with secondary generalization; syncope; spon-
taneous abortion; drug rash with eosinophilia and sys-
temic symptoms (DRESS); and pruritic rash (1 event
in 1 patient each). Most serious AEs occurred during
the AED conversion period (2.3% of all patients). There
were no deaths during the 18-week double-blind period.
One patient died due to a convulsion during the baseline
period, before receiving study drug.
Overall, 16 patients (9%) discontinued the study due
to a TEAE (3% on ESL 1200 mg versus 12% on ESL
1600 mg). Thirteen patients (8%) discontinued due to
TEAE that was potentially related to ESL. The most
common TEAEs leading to study discontinuation were
complex partial seizures (2.3%) and pruritic rash (1.2%).
More TEAEs leading to discontinuation were reported
during the titration period (5%) than the AED conver-
sion period (2%) and the monotherapy period (2%). The
frequency of dose reductions due to TEAEs was similar
between the ESL 1200 mg group (5%) and the ESL
1600 mg group (4%); dose reductions occurred only dur-
ing the AED conversion period.
Most clinical laboratory parameters were comparable
between treatment groups. Decreased plasma sodium
(125–135 mEq/L) was noted in 75% and 58% of patients
on ESL 1600 and 1200 mg, respectively; no patients had
plasma sodium <125 mEq/L. 15% of patients had a
reduction in plasma sodium ≥10 mEq/L from baseline at
some time during the 18-week double-blind period.
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no orthostatic effects, no significant abnormalities in
physical and neurological examinations in either treat-
ment group, and no clinically significant electrocardio-
gram findings. Suicidality (assessed using the Columbia
Suicide Severity Rating Scale [C-SSRS] questionnaire)
was reported post baseline in 3% of the ESL 1600 mg
group and 3% of the ESL 1200 mg group. Suicidality was
not reported as a TEAE.
Discussion
The current study met its primary efficacy endpoint (the
proportion of patients who exited the study on meeting
at least one exit criterion, e.g., due to poor seizure con-
trol) by demonstrating that the exit rates for patients
who converted to ESL monotherapy (both dose levels)
were <16% and were statistically lower than the exit
rates in the pseudo-placebo arms of the historical con-
trol trials. Thus, the efficacy of ESL monotherapy (1600
and 1200 mg QD) for seizure control was demonstrated
to be superior to the historical control.
Exit rates for patients who took CBZ during the base-
line period were numerically higher than for those not
taking CBZ. In their analysis of eight study cohorts,
French et al. [17] found that withdrawal from CBZ did
not significantly increase the likelihood of exiting a trial,
but increased the hazard rate of exiting by 8.0% [95% CI
–19.4, 35.4%]. In the current trial, both patient sub-
groups (CBZ users and non-users) had exit rates that
were significantly different from the 65.3% threshold. It
should be noted, however, that this threshold was com-
puted for the total historical group, including both users
and non-users of CBZ [17]. In the current trial, exit rates
for patients receiving valproic acid at baseline were nu-
merically lower than for patients not receiving valproic
acid as a baseline AED.
There was a reduction in standardized seizure fre-
quency (in both ESL dose groups) from baseline across
different seizure types; due to the small sample size for
patients with simple partial seizures without motor
symptoms, it was not possible to draw conclusions about
the efficacy of ESL for this type of seizure.
The improvements observed with ESL in several of the
secondary efficacy endpoints (proportion of seizure-free
patients during monotherapy; reduction in standardized
seizure frequency; responder rate) are consistent with
the suggestion that ESL monotherapy is a potential
treatment option for patients with POS.
A 4-point improvement in QOLIE-31 score occurred
in both ESL treatment groups, suggesting that patients
perceived some improvement in their quality of life.
However, according to Borghs et al. [23], the mini-
mum clinically relevant improvement in QOLIE-31
score is a 5-point improvement, which indicates thatthe improvement in QOLIE-31 that occurred during the
current trial may not be clinically relevant. A longer
period of observation may be required to identify changes
in quality of life. In contrast, the improvement in depres-
sive symptoms during treatment with ESL 1600 mg (as
indicated by a 1.6-point reduction in MADRS score) does
appear to be clinically relevant, being comparable to the
minimal clinically important difference (a 1.6–1.9 point
improvement) described by Duru and Fantino [24]. In
patients with at least mild depressive symptoms at base-
line (MADRS scores ≥14), clinically important differences
in MADRS scores were seen in both ESL treatment
groups.
The majority of patients (>75%) completed the 10-
week monotherapy period and the total (18-week)
study period, indicating that ESL monotherapy was
well tolerated. Compared with the safety profile of ESL
determined in the earlier adjunctive trials, no new
safety issues were raised during the current trial, and
the AEs observed were consistent with the previously
reported safety profile of ESL [10]. The most com-
monly reported TEAEs were headache and dizziness,
of mild to moderate severity. TEAEs were reported
more frequently by patients on ESL 1600 mg than by
those on ESL 1200 mg. Severe TEAEs were only re-
ported for the ESL 1600 mg dose group, during the
AED conversion and monotherapy periods. Serious
AEs were mostly reported for the 1600 mg ESL group;
the incidence of serious AEs was low during the
monotherapy period. The TEAEs that most often led
to study discontinuation were complex partial seizures
and pruritic rash (incidence <2.5% each). There were
no treatment-emergent deaths.
This study adopted the “historical control withdrawal
to monotherapy design” described by French et al. [17]
to evaluate the safety and efficacy of ESL monotherapy
in adults with POS not well controlled by one or two
AEDs. The use of a historical control is a potential limi-
tation of this study. The historical control withdrawal to
monotherapy study design is regarded as ethical and
reliable for investigating the efficacy of AEDs in the
monotherapy setting [17]. The fact that the design,
patient population, evaluation criteria, and analysis plan
of the current study are comparable to those of the
historical control studies means that it is justifiable to
compare the respective exit rates [25]. One factor that
may have influenced the results is that the proportion of
patients taking CBZ at baseline in this study was lower
(28.6% overall) than in the historical control trials (see
Additional file 1: Table S2). As patients who have con-
verted from CBZ-based therapy have been shown to
exhibit higher exit rates than others, this might contrib-
ute to the differences in overall exit rates between the
current trial and the historical control. The use of
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come, because all patients would have been aware that
they were receiving active treatment. However, this was
also the case for the historical comparator trials (which
used a “pseudo-placebo” comparator). Moreover, the in-
fluence of this effect should be minimized by the blinded
randomization to the two dose arms used in this study.
Previous studies have indicated that patients can experi-
ence a ‘honeymoon period’ when beginning with a new
AED; patients may show initial improvement, but may
become resistant on exposure to prolonged treatment
[26,27]. This is often due to pharmacokinetic or pharma-
codynamic tolerance [28]. The duration of the current
trial exceeded the estimated ‘honeymoon period’ (51–82
days with levetiracetam [27]), and was therefore of suffi-
cient duration to detect any similar tolerance with ESL.
A long-term open-label extension study is underway,
with the objective of evaluating whether the efficacy and
safety of ESL monotherapy is maintained during long-
term use.
Other recent epilepsy studies have used this approach
to investigate the use of AEDs as monotherapy (leveti-
racetam XR 2000 mg QD [29]; lamotrigine XR 300 and
250 mg QD [25]; lacosamide 300 and 400 mg/day [30];
pregabalin 600 mg/day [31]). All these studies recruited
patients from a mix of US and ex-US populations, as did
the current study, whereas the eight studies comprising
the historical control [17] were recruited exclusively
from North America. It is unclear whether this had an
important influence on the study results. It should also
be noted that there are subtle but potentially important
differences among these trials. The current study used a
stringent definition of the primary endpoint. First, once
the withdrawal rate had exceeded 10%, further with-
drawals were reassigned as seizure exits by random
sampling. Second, information from the seizure diaries
was used to evaluate seizure rate, and patients whose
rate at least doubled between baseline and the 16-week
study period were also reassigned as seizure exits (if the
investigator had not already done so). This was not done
in the levetiracetam XR, lamotrigine XR, lacosamide or
pregabalin trials. The lamotrigine XR trial excluded
patients using CBZ as a baseline medication, when CBZ
is known to affect the exit rate in studies of this design.
Therefore caution must be used when comparing exit
rates among these studies. Two conversion to monother-
apy trials of brivaracetam (ClinicalTrials.gov identifiers:
NCT00698581 and NCT00699283) using historical con-
trols were terminated after an interim analysis demon-
strated trial futility.
A second trial (study 045) examining the efficacy and
safety of ESL has been performed in a 100% North
American population [21], using an identical protocol.
The efficacy of ESL monotherapy for seizure control instudy 045 was also found to be superior to historical
controls. However, the Kaplan–Meier-estimated exit
rates in study 045 were higher (1600 mg: 28.7% [95% CI
21.2–38.1%]; 1200 mg: 44.4% [32.5–58.3%]) than the
rates observed in this study, potentially due to the differ-
ence in study populations.
Conclusions
The results of this phase III study demonstrate that
ESL monotherapy, following conversion from other ad-
junctive AEDs, was effective based on comparison with
a historical control. Additionally, during ESL mono-
therapy a substantial fraction of patients experienced a
reduction in seizure frequency compared with baseline.
The relatively high completion rate and the side effect
profile of ESL at doses of 1200 and 1600 mg QD indi-
cate that ESL was efficacious and well tolerated when
used as monotherapy.
Additional file
Additional file 1: Table S1. Baseline AEDs (EFF population). Table S2.
Demographic and clinical characteristics of patients in the trials
comprising the historical control. Appendix S1. Statistical analyses.
Appendix S2. The Study 046 team.
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